Pexali 100 mg, 500 mg Powder for concentrate for solution for infusion.
PDF Leaflet Revision Date: May 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of malignant pleural mesothelioma and non-small cell lung cancer.
Dosage (summary)
500 mg/mu00b2 IV infusion over 10 mins on day 1 of each 21-day cycle.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Avoid in pregnancy; not established in breastfeeding.
Key Drug Interactions
- Nephrotoxic agents
- NSAIDs
- Live vaccines
Contraindications
- Hypersensitivity to pemetrexed
- Concomitant yellow fever vaccine
Common side effects
- Nausea
- Fatigue
- Rash
- Decreased neutrophils
Counselling Points
- Take folic acid and vitamin B12
- Avoid pregnancy
- Monitor for signs of infection
Serious warnings
- Myelosuppression
- Risk of severe skin reactions
- Potential for irreversible infertility
Important Disclaimer
The Pexali 100 mg, 500 mg Powder for concentrate for solution for infusion. professional information leaflet below is the property of Abex Pharmaceutica and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
